Key Drivers
- Strong revenue
- High leverage
- Quarterly volatility
AIAI Summary
Organon's investment case has shifted from a commercialization-driven recovery to an execution- and deleveraging-driven bet—near-term upside now depends on predictable, repeatable quarter-to-quarter free cash flow and measurable net-debt reduction rather than multiple rerating. Actionable watchpoints: track quarterly FCF cadence, progress on announced divestitures/licensing proceeds, and Vtama/biosimilar uptake versus guidance—failure to hit these will rapidly amplify downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong revenue
- •High leverage
- •Quarterly volatility
OGN delivered strong FY revenue, gross margins and free cash flow but faces high long-term leverage, heavy intangible assets and recent quarterly losses that create significant financial risk.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Clustered lows
- •Failed reclaim
OGN is in a clear downtrend over the last month, falling roughly 25% from $8.08 to $6.03 with resistance near $7.2–$8.1 and support around $6.0–$6.4, where a break below $6.00 would likely open further downside while a reclaim above $7.2 would signal early recovery.
~25% drop from $8.08 to $6.03 over the last month indicating accelerated selling
Sentiment & News
Key News Insights:
- •Organon weakness
- •Dermatology progress
- •Orogen funded
Organon showed weak quarterly results with margin and debt priorities despite dermatology and contraceptive pipeline moves, while Orogen shelved a planned raise but remains funded and added a Nevada royalty—FDA seizure warnings for some Parkinson's drugs were also reported alongside these headlines.
Mixed fundamentals leave Organon under near‑term pressure while Orogen's balance‑sheet clarity limits downside risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings